Your browser is no longer supported. Please, upgrade your browser.
AIM AIM ImmunoTech Inc. daily Stock Chart
AIM ImmunoTech Inc.
Index- P/E- EPS (ttm)-8.31 Insider Own3.50% Shs Outstand4.93M Perf Week0.00%
Market Cap2.86M Forward P/E- EPS next Y-2.78 Insider Trans- Shs Float4.53M Perf Month-68.65%
Income-10.10M PEG- EPS next Q-0.97 Inst Own11.60% Short Float10.76% Perf Quarter-80.67%
Sales0.30M P/S9.53 EPS this Y22.90% Inst Trans- Short Ratio0.96 Perf Half Y-90.91%
Book/sh2.81 P/B0.21 EPS next Y37.90% ROA-68.60% Target Price4.00 Perf Year-93.96%
Cash/sh0.59 P/C0.99 EPS next 5Y25.00% ROE-219.80% 52W Range0.52 - 14.81 Perf YTD-92.72%
Dividend- P/FCF- EPS past 5Y28.20% ROI-99.30% 52W High-96.18% Beta0.89
Dividend %- Quick Ratio2.10 Sales past 5Y19.60% Gross Margin- 52W Low8.43% ATR0.18
Employees31 Current Ratio2.10 Sales Q/Q-12.10% Oper. Margin- RSI (14)28.03 Volatility10.88% 16.71%
OptionableNo Debt/Eq0.89 EPS Q/Q55.10% Profit Margin- Rel Volume0.20 Prev Close0.58
ShortableYes LT Debt/Eq0.85 Earnings- Payout- Avg Volume509.73K Price0.57
Recom2.00 SMA20-15.26% SMA50-59.49% SMA200-89.37% Volume82,714 Change-2.41%
Oct-07-19 06:30AM  AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified ACCESSWIRE +7.23%
Sep-25-19 09:50AM  AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering ACCESSWIRE -43.37%
Sep-24-19 06:30AM  AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center ACCESSWIRE -14.53%
06:00AM  AIM ImmunoTechs Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome ACCESSWIRE
Sep-19-19 08:43AM  AIM ImmunoTech Shares Spike Up 90% After $6.42M 'Breakthrough Award' Benzinga +32.91%
06:50AM  AIM ImmunoTech Inc. Announces the U.S. Department of Defenses Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer ACCESSWIRE
Sep-16-19 06:50AM  AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer ACCESSWIRE
Sep-13-19 06:50AM  AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City ACCESSWIRE
Sep-10-19 07:30AM  AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center ACCESSWIRE
Sep-09-19 07:45AM  AIM ImmunoTech Inc. Announces its Name Change is Complete, Its New Website is Up and the Company Now Trades as Ticker Symbol 'AIM' ACCESSWIRE
Sep-06-19 06:30AM  AIM ImmunoTech to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 10th ACCESSWIRE
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.